| Title: | Identification of risk factors for developing Progressive Supranuclear Palsy (PSP) using the UK Biobank |
| Lead Institution: | Massachusetts General Hospital |
| Principal investigator: |
Application 633516
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Objective: The aim of this study is to identify potential risk factors associated with the development of Progressive Supranuclear Palsy (PSP) by leveraging data from the UK Biobank. Scientific Questions: What are the environmental and clinical risk factors that contribute to the development of PSP in individuals without the disease at baseline? Are there medical comorbidities, environmental exposures, and lifestyle factors associated with the subsequent development of PSP? Rationale: PSP is a rare neurodegenerative disorder that presents with motor, cognitive, and behavioral dysfunction. The most common form is Richardson syndrome, characterized by atypical parkinsonism and oculomotor abnormalities. Unlike for idiopathic Parkinson's disease (PD), environmental and other risk factors for developing PSP have not been shown in large prospective studies due to the rarity of the disease and its progressive nature, making identifying early biomarkers and risk factors challenging. Prior retrospective studies are limited by selection and recall bias, but suggest environmental, toxic, socio-economic, and comorbid medical risk factors linked to developing PSP (Park 2021, PMID: 34062646). These risk factors have yet to be verified in a prospective longitudinal study in patients without the disease at baseline. The UK Biobank represents a unique opportunity to leverage a large database with comprehensive clinical, environmental and socio-economic data to investigate risk factors for developing PSP. The Biobank contains more than 170 cases of PSP and 2500 cases of Parkinson disease, which have been used to identify prodromal PSP features (Street 2022, PMID: 35032742). We hope to use these cases to identify risk factors for developing PSP in this population, which will improve our understanding of PSP etiology and identify potential early intervention or preventive opportunities.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 18214 | Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank | Charlie Weige Zhao (+11) | 2026 | Movement Disorders |
Enabling scientific discoveries that improve human health